{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:40:13Z","timestamp":1789850413608,"version":"4.0.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ccm.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T20:30:54Z","timestamp":1382128254000},"page":"825-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Parenteral and Inhaled Prostanoid Therapy in the Treatment of Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"34","author":[{"given":"Vallerie V.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold I.","family":"Palevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ccm.2013.09.003_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"8385","key":"10.1016\/j.ccm.2013.09.003_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2013.09.003_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.09.003_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"12 Suppl S","key":"10.1016\/j.ccm.2013.09.003_bib5","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.003_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1164\/ajrccm.164.2.2010150","article-title":"Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling","volume":"164","author":"Hoshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"10.1016\/j.ccm.2013.09.003_bib8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1161\/CIRCULATIONAHA.104.503540","article-title":"Pulmonary arterial hypertension","volume":"114","author":"McLaughlin","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","article-title":"Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery","volume":"26","author":"Clapp","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5614","key":"10.1016\/j.ccm.2013.09.003_bib10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/267850a0","article-title":"Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets","volume":"267","author":"Best","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.ccm.2013.09.003_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/pcad.2002.130041","article-title":"Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension","volume":"45","author":"Jeffery","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"issue":"1\u20134","key":"10.1016\/j.ccm.2013.09.003_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.prostaglandins.2006.05.011","article-title":"Cardioprotective prostacyclin signaling in vascular smooth muscle","volume":"82","author":"Fetalvero","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.ccm.2013.09.003_bib14","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1161\/01.CIR.96.9.2782","article-title":"Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension","volume":"96","author":"Friedman","year":"1997","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.003_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1055\/s-0038-1653857","article-title":"Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension","volume":"73","author":"Boyer-Neumann","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":"Prostacyclin and its analogues in the treatment of pulmonary hypertension","volume":"102","author":"Olschewski","year":"2004","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ccm.2013.09.003_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0031-6989(83)80003-4","article-title":"Positive inotropic effect of a stable analogue of PGI2 and of PGI2 on isolated guinea pig atria. Mechanism of action","volume":"15","author":"Fassina","year":"1983","journal-title":"Pharmacol Res Commun"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.003_bib18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bjp.0707300","article-title":"Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes","volume":"151","author":"Fontana","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ccm.2013.09.003_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/DDDT.S31628","article-title":"Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Devel Ther"},{"issue":"16","key":"10.1016\/j.ccm.2013.09.003_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2146\/ajhp110687","article-title":"A\u00a0new epoprostenol formulation for the treatment of pulmonary arterial hypertension","volume":"69","author":"Fuentes","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccm.2013.09.003_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2013.09.003_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2013.09.003_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.09.003_bib25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.003_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.09.003_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.117.1.14","article-title":"Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus","volume":"117","author":"Robbins","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.09.003_bib28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2013.09.003_bib29","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1161\/01.CIR.89.6.2722","article-title":"Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension","volume":"89","author":"Petitpretz","year":"1994","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.003_bib30","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1164\/ajrccm.162.5.2004042","article-title":"Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension","volume":"162","author":"Aguilar","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.003_bib31","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.003_bib32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00007890-199702270-00020","article-title":"Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension","volume":"63","author":"Kuo","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.ccm.2013.09.003_bib33","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","article-title":"The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension","volume":"34","author":"Rich","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.003_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/0091270003261343","article-title":"Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.003_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0091270004264638","article-title":"Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.003_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pupt.2011.01.002","article-title":"Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension","volume":"24","author":"Walkey","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.003_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0091270007309708","article-title":"Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion","volume":"48","author":"McSwain","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccm.2013.09.003_bib40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.003_bib41","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ccm.2013.09.003_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.healun.2012.02.025","article-title":"Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension","volume":"31","author":"Sadushi-Kolici","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.ccm.2013.09.003_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1538-7836.2007.02394.x","article-title":"Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension","volume":"5","author":"Skoro-Sajer","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.003_bib45","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.09.003_bib46","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1378\/chest.121.5.1561","article-title":"Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension","volume":"121","author":"Vachiery","year":"2002","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ccm.2013.09.003_bib47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00003088-200847090-00004","article-title":"A\u00a0clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension","volume":"47","author":"Skoro-Sajer","year":"2008","journal-title":"Clin Pharm"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccm.2013.09.003_bib49","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/112972980600700304","article-title":"Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension","volume":"7","author":"Tapson","year":"2006","journal-title":"J\u00a0Vasc Access"},{"issue":"11","key":"10.1016\/j.ccm.2013.09.003_bib52","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1164\/ajrccm.186.11.1196","article-title":"A\u00a0case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy","volume":"186","author":"Ewert","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.003_bib53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1086\/529552","article-title":"Bloodstream infections in patients given treatment with intravenous prostanoids","volume":"29","author":"Kallen","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"10.1016\/j.ccm.2013.09.003_bib54","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.mayocp.2012.05.014","article-title":"Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R)","volume":"87","author":"Kitterman","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"10.1016\/j.ccm.2013.09.003_bib55","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.003_bib56","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.ccm.2013.09.003_bib57","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.ccm.2013.09.003_bib58","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"160","key":"10.1016\/j.ccm.2013.09.003_bib59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1742-1241.2008.01811.x","article-title":"Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension","author":"Doran","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"8","key":"10.1016\/j.ccm.2013.09.003_bib60","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.healun.2010.03.008","article-title":"Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey","volume":"29","author":"Kingman","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.003_bib61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ahj.2008.10.029","article-title":"Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review","volume":"157","author":"Oudiz","year":"2009","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.003_bib62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00614197","article-title":"Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man","volume":"30","author":"Krause","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.003_bib63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/ecp.10.136","article-title":"Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension","volume":"4","author":"John","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib64","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1183\/09031936.02.00094302","article-title":"Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation","volume":"19","author":"Beghetti","year":"2002","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2013.09.003_bib65","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.003_bib66","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/clc.21987","article-title":"Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study","volume":"35","author":"Sun","year":"2011","journal-title":"Clin Cardiol"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.003_bib67","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"111","key":"10.1016\/j.ccm.2013.09.003_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1183\/09059180.00011111","article-title":"Inhaled iloprost for the treatment of pulmonary hypertension","volume":"18","author":"Olschewski","year":"2009","journal-title":"Eur Respir Rev"},{"issue":"25","key":"10.1016\/j.ccm.2013.09.003_bib69","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.ccm.2013.09.003_bib70","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccm.2013.09.003_bib71","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.ccm.2013.09.003_bib72","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.003_bib73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/2045-8932.114768","article-title":"A\u00a0multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost","volume":"3","author":"Channick","year":"2013","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.003_bib74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11630780-000000000-00000","article-title":"Cost effectiveness of prostacyclins in pulmonary arterial hypertension","volume":"10","author":"Roman","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ccm.2013.09.003_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/DDDT.S19281","article-title":"Inhaled treprostinil: a therapeutic review","volume":"6","author":"Channick","year":"2012","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.003_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pupt.2008.11.009","article-title":"Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension","volume":"22","author":"Voswinckel","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ccm.2013.09.003_bib77","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jacc.2006.05.070","article-title":"Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension","volume":"48","author":"Channick","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.003_bib78","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.pupt.2008.07.003","article-title":"Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension","volume":"21","author":"Voswinckel","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.ccm.2013.09.003_bib79","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ccm.2013.09.003_bib80","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.ccm.2013.09.003_bib81","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.amjcard.2012.07.012","article-title":"Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension","volume":"110","author":"de Jesus Perez","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.003_bib82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1755-5922.12008","article-title":"Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension","volume":"31","author":"Bourge","year":"2013","journal-title":"Cardiovasc Ther"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:49:54Z","timestamp":1759452594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523113001330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0272523113001330"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2013.09.003","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parenteral and Inhaled Prostanoid Therapy in the Treatment of Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}